

CTI - Antithrombotics February 2010

Adis Clinical Trials Insight: Ongoing Trials - Status Tracking February 2010

The table below highlights the ongoing trials whose status has changed during February 2010

Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
1 700035244	Paclitaxel	Active, no longer recruiting	III	Paclitaxel: therapeutic use Prevention of coronary artery restenosis Drug-eluting stents in patients with myocardial ischaemia	Braun Melsungen
2 700038988	Aspirin Phenprocoumon	Active, no longer recruiting	III	Phenprocoumon vs aspirin: adverse reactions Calcinosis	
3 700022000	Defibrotide	Completed	II/III	Defibrotide: therapeutic use Prevention of veno-occlusive disorders In paediatric stem cell transplant recipients	Gentium
4 700052101	Drotrecogin-alfa	Completed	IV	Drotrecogin alfa: therapeutic use Prevention of thrombosis In France	Eli Lilly
5 700041187	ILS-920	Completed	I	ILS 920: adverse reactions Various toxicities In volunteers	Wyeth
6 700046502	Tenecteplase	Recruiting	II/III	Tenecteplase: therapeutic use Stroke	Emcure Pharmaceuticals
7 700048412	Alternative-medicine Aspirin	Recruiting	IV	Aspirin: therapeutic use Stroke In combination with traditional Chinese medicine to improve clinical outcome in patients with ischaemic disease: cost-analysis trial	
8 700044192	Heparin	Recruiting	III	Heparin: pharmacodynamics Effect on anti-XA levels, activated partial thromboplastin time and activated clotting time Effects of heparin of porcine origin (Hipolabor) in patients undergoing heart surgery	
9 700031282	Warfarin	Completed	II	Warfarin: therapeutic use Prevention of deep vein thrombosis, pulmonary embolism, thromboembolism Phase II trial in patients undergoing transvenous cardiac device	

CTI - Antithrombotics February 2010

Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
10 700049892	Aspirin Clopidogrel	Active, no longer recruiting	III	Aspirin +/- clopidogrel: therapeutic use Transient ischaemic attacks, Stroke The POINT trial	
11 700037477	Sirolimus	Completed	IV	Sirolimus: therapeutic use Prevention of coronary artery restenosis In patients with angina pectoris	Cordis Corporation
12 700012888	Antithrombotics Aspirin Clopidogrel Dipyridamole Warfarin	Recruiting	II	Antithrombotics: therapeutic use Stroke Patent foramen ovale closure vs standard therapy in patients with recurrent disease	
13 700025752	Apixaban Aspirin	Active, no longer recruiting	III	Apixaban vs aspirin: therapeutic use Prevention of thromboembolism, stroke Phase III trial in patients with atrial fibrillation: the AVERROES trial	Bristol-Myers Squibb, Pfizer
14 700025604	Bemiparin-sodium Heparin	Discontinued	III	Bemiparin sodium vs heparin: therapeutic use Prevention of thromboembolism In patients receiving long-term oral anticoagulant therapy: The BERTA trial	
15 700052174	Cilostazol Probucol	Recruiting	IV	Cilostazol +/- probucol: therapeutic use Atherosclerosis Effect on plaque stabilisation and lesion regression	Otsuka Pharmaceutical
16 700032728	Clopidogrel	Recruiting	III	Clopidogrel: therapeutic use Stroke In patients with acute, ischaemic disease	
17 700009276	Dalteparin-sodium	Completed	II	Dalteparin sodium: pharmacodynamics Effect on disease response Phase II trial in patients with ovarian cancer receiving taxane- and platinum-based chemotherapy: FOCUS	Pfizer
18 700027623	Paclitaxel	Active, no longer recruiting	I/II	Paclitaxel: adverse reactions Various toxicities Phase I/II trial	Abraxis BioScience

CTI - Antithrombotics February 2010

Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
19 700046860	Paclitaxel	Active, no longer recruiting	IV	Paclitaxel: therapeutic use Prevention of coronary artery restenosis Drug-eluting stents in patients with with de novo coronary lesions undergoing angioplasty	Sahajanand Medical Technologies
20 700028976	Paclitaxel	Completed	II/III	Paclitaxel: therapeutic use Prevention of coronary artery restenosis Drug-eluting stents versus brachytherapy	Boston Scientific Corporation
21 700027758	Paclitaxel	Completed	II/III	Paclitaxel: therapeutic use Prevention of coronary artery restenosis Drug-eluting stents vs bare stents in patients with de novo lesions	Boston Scientific Corporation
22 700043330	Paclitaxel	Completed	IV	Paclitaxel: therapeutic use Prevention of coronary artery restenosis Drug-eluting stents vs bare stents in patients with type 2 diabetes mellitus	Translumina Labs
23 700037769	Paclitaxel	Completed	III	Paclitaxel: therapeutic use Prevention of coronary artery restenosis In patients undergoing drug eluting stent implantation and percutaneous coronary intervention	Boston Scientific Corporation
24 700025898	Sirolimus	Completed	IV	Sirolimus: therapeutic use Prevention of coronary artery restenosis Cost effectiveness of drug-eluting vs bare metal stents in patients with diabetes	Cordis Corporation
25 700037044	ARC-1779	Discontinued	II	ARC 1779: therapeutic use Cerebral embolism In patients undergoing carotid endarterectomy	Archemix Corporation
26 700038893	Antiretrovirals Aspirin	Active, no longer recruiting	II	Aspirin + antiretrovirals: pharmacodynamics Assessing effect on cardiovascular risk In patients with HIV infections	
27 700039798	Edoxaban Warfarin	Completed	II	Edoxaban vs warfarin: adverse reactions Haemorrhage In patients with non-valvular atrial fibrillation	Daiichi Sankyo Company, Daiichi Sankyo Inc
28 700035549	Paclitaxel	Completed	IV	Paclitaxel: therapeutic use Prevention of coronary artery restenosis In patients with multivessel coronary artery disease	Boston Scientific Corporation

CTI - Antithrombotics February 2010

Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
29 700035606	Zotarolimus	Completed	III	Zotarolimus: therapeutic use Prevention of coronary artery restenosis Drug-eluting stents vs bare metal stent in patients with acute myocardial infarction	Medtronic
30 700053686	Everolimus Paclitaxel	Recruiting	III	Paclitaxel vs everolimus: therapeutic use Prevention of coronary artery restenosis Drug-eluting Xience V stent (Abbott Vascular) vs SeQuent Please balloon (BBraun); an optical coherence tomography evaluation	
31 700041134	Warfarin	Completed	IV	Warfarin: pharmacodynamics Effects of CYP 2C9 and VKORC1 polymorphisms on time to achieve stable dosages Cost-analysis trial in typical community practice settings	
32 700024432	Rivaroxaban Warfarin	Completed	III	Rivaroxaban vs warfarin: therapeutic use Prevention of stroke and thromboembolism Phase III trial in Japanese patients with atrial fibrillation	Bayer, Johnson & Johnson, Johnson & Johnson Pharmaceutical Research & Development
33 700045842	Enoxaparin-sodium YM-150	Active, no longer recruiting	II/III	YM-150 vs enoxaparin sodium: therapeutic use Prevention of pulmonary embolism, deep vein thrombosis, thrombosis In patients undergoing elective total hip replacement surgery	Astellas Pharma
34 700030954	E-5555	Completed	II	E 5555: adverse reactions Various toxicities In Japanese patients with acute coronary syndrome	Eisai Medical Research

For further information, please call +44 (0) 20 7981 0765 or send an e-mail to clientsupport@wolterskluwer.com.